VIRACTA THERAPEUTICS

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

13 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

06 Nov 2024 16:30:00 By Nasdaq GlobeNewswire

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

14 Aug 2024 07:05:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

14 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Announces New Employment Inducement Grants

17 May 2024 16:05:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

14 May 2024 07:00:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

09 May 2024 16:05:01 By Nasdaq GlobeNewswire

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

07 May 2024 16:05:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma

15 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

01 Apr 2024 08:30:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

07 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial

29 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Provides Clinical Update and Outlook for 2024

04 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma

12 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels

04 Dec 2023 08:30:00 By Nasdaq GlobeNewswire

Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

09 Nov 2023 08:30:00 By Nasdaq GlobeNewswire

Viracta Therapeutics to Present at Upcoming Investor Conferences

07 Nov 2023 16:15:00 By Nasdaq GlobeNewswire

Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers

04 Oct 2023 07:00:00 By Nasdaq GlobeNewswire